<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01122134</url>
  </required_header>
  <id_info>
    <org_study_id>CPR 07</org_study_id>
    <nct_id>NCT01122134</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate for Severe Malaria Treatment</brief_title>
  <official_title>Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate in Treatment of Severe Malaria in Ugandan Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Makerere University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravenous artesunate is highly effective with rapid schizonticidal action and improved
      clinical outcome
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current first line treatment for severe malaria in Uganda is intravenous quinine with
      artemisinin derivatives as an alternative. Intravenous artesunate, a water soluble
      artemisinin derivative is more effective than quinine with faster schizonticidal action and
      improved clinical outcome. It is generally well tolerated and safe. This study aims is to
      assess the pharmacokinetics, pharmacodynamics and safety of IV artesunate in treatment of
      severe malaria in adults admitted to Mulago National Referral and Teaching hospital, Uganda.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">September 2010</completion_date>
  <primary_completion_date type="Anticipated">August 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters; total area under the plasma concentration vs. time curve (AUC) of artesunate and DHA, maximum plasma concentration (Cmax), time to attain maximum concentration, elimination half life</measure>
    <time_frame>6 hours</time_frame>
    <description>Pharmacokinetic parameters for artesunate and dihydroartemisinin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to 50% parasite clearance (PCT50)</measure>
    <time_frame>7 days</time_frame>
    <description>Time to 50% parasite clearance (PCT50) parasite clearance rates and clinical recovery</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Severe Malaria</condition>
  <arm_group>
    <arm_group_label>20 adults with severe malaria</arm_group_label>
    <description>20 adult patients admitted with severe malaria</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous artesunate</intervention_name>
    <description>Intravenous artesunate in a dose of 2.4 mg/kg at start of treatment, 2.4 mg/kg 12 hours later and 2.4 mg/kg/day until the patient is able to tolerate oral therapy. The minimum duration of IV treatment will be 24 hours.</description>
    <arm_group_label>20 adults with severe malaria</arm_group_label>
    <other_name>ArtesunÂ®</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples collected for artesunate drug assays
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The target population for this study are patients aged 18 years and above. The accessible
        population will be patients of 18 years and above who present to Mulago hospital with
        severe malaria. The study population will include patients aged 18 years and above
        presenting with severe malaria, who fulfill study eligibility criteria and are enrolled.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged 18 years and above

          2. With severe malaria according to the following ciriteria:

          3. A positive blood smear for malaria with P. falciparum mono-infection with parasitemia
             &gt; 500 parasites/ul of blood

          4. Who according to the attending physician require parenteral treatment and admission
             for malaria

          5. Willing to participate in the study

          6. Who are or whose first degree parents/caretakers are able to provide written informed
             consent

        Exclusion Criteria:

          1. Patients with history of prior antimalarial use within the last 72 hours

          2. Pregnant women

          3. Patients with contraindications to taking the study drugs

          4. Patients taking known inhibitors or inducers of cytochrome P450 -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pauline Byakika-Kibwika, MSc, MMed</last_name>
    <role>Principal Investigator</role>
    <affiliation>Makerere University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mulago National Referral hospital</name>
      <address>
        <city>Kampala</city>
        <zip>256</zip>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pauline Byakika-Kibwika, MSc, MMed</last_name>
      <phone>+256 772 626885</phone>
      <email>pbyakika@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mohammed Lamorde, MBBS</last_name>
      <phone>+256 772 185590</phone>
      <email>mlamorde@idi.co.ug</email>
    </contact_backup>
    <investigator>
      <last_name>Pauline Byakika-Kibwika, MSc, MMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ceppie Merry, FRCP, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohammed Lamorde, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harriet Mayanja-Kizza, MSc, MMed</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Celestino Obua, MSc, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2010</study_first_submitted>
  <study_first_submitted_qc>May 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2010</study_first_posted>
  <last_update_submitted>May 10, 2010</last_update_submitted>
  <last_update_submitted_qc>May 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Pauline Byakika-Kibwika</name_title>
    <organization>INTERACT, Makerere University</organization>
  </responsible_party>
  <keyword>severe</keyword>
  <keyword>malaria</keyword>
  <keyword>artesunate</keyword>
  <keyword>intravenous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

